On the public citation graph
Biotech IPOs and Drug Development Disclosure
0 signed · 55 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2010.207openalex-extracted
Registering Clinical Trial Results
inferredcites →https://doi.org/10.1001/jamainternmed.2021.2036openalex-extracted
Evaluation of Compliance With Legal Requirements Under the FDA Amendments Act of 2007 for Timely Registration of Clinical Trials, Data Verification, Delayed Reporting, and Trial Document Submission
inferredcites →https://doi.org/10.1001/jamanetworkopen.2022.31609openalex-extracted
Estimated Cost of Developing a Therapeutic Complex Medical Device in the US
inferredcites →https://doi.org/10.1002/mde.1360openalex-extracted
The cost of biopharmaceutical R&D: is biotech different?
inferredcites →https://doi.org/10.1007/s11142-013-9223-1openalex-extracted
A theory of voluntary disclosure and cost of capital
inferredcites →https://doi.org/10.1016/0304-405x(76)90026-xopenalex-extracted
Theory of the firm: Managerial behavior, agency costs and ownership structure
inferredcites →https://doi.org/10.1016/0304-405x(86)90055-3openalex-extracted
Investment banking, reputation, and the underpricing of initial public offerings
inferredcites →https://doi.org/10.1016/j.irfa.2022.102047openalex-extracted
Time to acquire: Regulatory burden and M&A activity
inferredcites →https://doi.org/10.1016/j.jacbts.2016.03.009openalex-extracted
Drugs, Devices, and the FDA: Part 2
inferredcites →https://doi.org/10.1016/j.jcorpfin.2020.101745openalex-extracted
The external financing of investment
inferredcites →https://doi.org/10.1016/j.jedc.2009.04.003openalex-extracted
Innovation and growth through local and global interaction
inferredcites →https://doi.org/10.1016/j.jfineco.2006.05.006openalex-extracted
Executive stock options and IPO underpricing
inferredcites →https://doi.org/10.1016/j.jfineco.2014.11.012openalex-extracted
The JOBS Act and IPO volume: Evidence that disclosure costs affect the IPO decision
inferredcites →https://doi.org/10.1016/j.jfineco.2019.12.003openalex-extracted
Agency conflicts and short- versus long-termism in corporate policies
inferredcites →https://doi.org/10.1016/j.jfineco.2022.12.004openalex-extracted
Common ownership and innovation efficiency
inferredcites →https://doi.org/10.1016/j.jhealeco.2009.08.004openalex-extracted
Trials, tricks and transparency: How disclosure rules affect clinical knowledge
inferredcites →https://doi.org/10.1016/j.jhealeco.2016.01.012openalex-extracted
Innovation in the pharmaceutical industry: New estimates of R&D costs
inferredcites →https://doi.org/10.1016/s0047-2727(00)00155-9openalex-extracted
The effect of tax subsidies to employer-provided supplementary health insurance: evidence from Canada
inferredcites →https://doi.org/10.1017/s0022109021000284openalex-extracted
Competition and R&D Financing: Evidence From the Biopharmaceutical Industry
inferredcites →https://doi.org/10.1038/nbt.4023openalex-extracted
Just how good an investment is the biopharmaceutical sector?
inferredcites →https://doi.org/10.1056/nejmsr1611785openalex-extracted
Trial Reporting in ClinicalTrials.gov — The Final Rule
inferredcites →https://doi.org/10.1093/biostatistics/kxx069openalex-extracted
Estimation of clinical trial success rates and related parameters
inferredcites →https://doi.org/10.1093/rcfs/cfac039openalex-extracted
Deregulating Innovation Capital: The Effects of the JOBS Act on Biotech Startups
inferredcites →https://doi.org/10.1093/rfs/hhs070openalex-extracted
Incentives to Innovate and the Decision to Go Public or Private
inferredcites →https://doi.org/10.1111/0022-1082.00079openalex-extracted
Earnings Management and the Long‐Run Market Performance of Initial Public Offerings
inferredcites →https://doi.org/10.1111/1475-679x.12172openalex-extracted
The JOBS Act and the Costs of Going Public
inferredcites →https://doi.org/10.1111/1475-679x.12396openalex-extracted
Do Mandatory Disclosure Requirements for Private Firms Increase the Propensity of Going Public?
inferredcites →https://doi.org/10.1111/j.1475-679x.2004.00140.xopenalex-extracted
Competitive Costs of Disclosure by Biotech IPOs
inferredcites →https://doi.org/10.1111/j.1475-679x.2007.00229.xopenalex-extracted
Disclosure of Intended Use of Proceeds and Underpricing in Initial Public Offerings
inferredcites →https://doi.org/10.1111/j.1540-6261.2008.01431.xopenalex-extracted
Financing Innovation and Growth: Cash Flow, External Equity, and the 1990s R&D Boom
inferredcites →https://doi.org/10.1111/j.1540-6261.2009.01540.xopenalex-extracted
The Variability of IPO Initial Returns
inferredcites →https://doi.org/10.1111/j.1745-6622.2010.00272.xopenalex-extracted
It Ain't Broke: The Past, Present, and Future of Venture Capital
inferredcites →https://doi.org/10.1111/jofi.12275openalex-extracted
Does Going Public Affect Innovation?
inferredcites →https://doi.org/10.1126/science.1153632openalex-extracted
Moving Toward Transparency of Clinical Trials
inferredcites →https://doi.org/10.1136/neurintsurg-2012-010400openalex-extracted
The FDA approval process for medical devices: an inherently flawed system or a valuable pathway for innovation?
inferredcites →https://doi.org/10.1146/annurev-financial-031721-081537openalex-extracted
Financing Biomedical Innovation
inferredcites →https://doi.org/10.1146/annurev-financial-111914-041825openalex-extracted
Financing Innovation
inferredcites →https://doi.org/10.1287/mnsc.2015.2350openalex-extracted
Financing Risk and Innovation
inferredcites →https://doi.org/10.1287/mnsc.2020.3775openalex-extracted
Trials and Terminations: Learning from Competitors’ R&D Failures
inferredcites →https://doi.org/10.1287/mnsc.2021.4243openalex-extracted
Find and Replace: R&D Investment Following the Erosion of Existing Products
inferredcites →https://doi.org/10.2139/ssrn.2459591openalex-extracted
The Jobs Act and IPO Volume: Evidence that Disclosure Costs Affect the IPO Decision
inferredcites →https://doi.org/10.2139/ssrn.3240344openalex-extracted
Find and Replace: R&D Investment Following the Erosion of Existing Products
inferredcites →https://doi.org/10.2139/ssrn.3344942openalex-extracted
Do Firms Respond to Peer Disclosures? Evidence from Disclosures of Clinical Trial Results
inferredcites →https://doi.org/10.2139/ssrn.384620openalex-extracted
Disclosure of Intended Use of Proceeds and Underpricing in Initial Public Offerings
inferredcites →https://doi.org/10.2139/ssrn.4249494openalex-extracted
Financial Intermediation and the Funding of Biomedical Innovation: A Review
inferredcites →https://doi.org/10.2307/2297419openalex-extracted
Innovation and Communication: Signalling with Partial Disclosure
inferredcites →https://doi.org/10.2307/2490187openalex-extracted
Financial Disclosure and Entry to the European Capital Market
inferredcites →https://doi.org/10.2308/accr-51721openalex-extracted
The JOBS Act and Information Uncertainty in IPO Firms
inferredcites →https://doi.org/10.2308/tar-2019-0137openalex-extracted
Do Firms Respond to Peer Disclosures? Evidence from Disclosures of Clinical Trial Results
inferredcites →https://doi.org/10.2308/tar-4478058openalex-extracted
Auditor Reputation and the Pricing of Initial Public Offerings.
inferredcites →https://doi.org/10.3386/w30594openalex-extracted
Financial Intermediation and the Funding of Biomedical Innovation: A Review
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.